FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 260 filers reported holding FATE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $238,332 | +136.3% | 63,725 | +34.0% | 0.01% | +100.0% |
| Q3 2023 | $100,840 | -17.3% | 47,566 | +85.7% | 0.00% | 0.0% |
| Q2 2023 | $121,908 | -90.4% | 25,611 | -88.5% | 0.00% | -91.4% |
| Q1 2023 | $1,268,826 | +204.5% | 222,601 | +439.0% | 0.04% | +191.7% |
| Q4 2022 | $416,687 | -40.2% | 41,297 | +32.7% | 0.01% | -47.8% |
| Q3 2022 | $697,000 | -23.7% | 31,111 | -15.6% | 0.02% | -14.8% |
| Q2 2022 | $913,000 | -31.2% | 36,850 | +7.5% | 0.03% | 0.0% |
| Q1 2022 | $1,328,000 | -23.9% | 34,264 | +15.0% | 0.03% | -20.6% |
| Q4 2021 | $1,744,000 | +19.6% | 29,799 | +21.1% | 0.03% | -8.1% |
| Q3 2021 | $1,458,000 | +767.9% | 24,598 | +1106.4% | 0.04% | +516.7% |
| Q1 2021 | $168,000 | -83.4% | 2,039 | -81.7% | 0.01% | -87.2% |
| Q4 2020 | $1,013,000 | +41.1% | 11,142 | -38.0% | 0.05% | +14.6% |
| Q3 2020 | $718,000 | – | 17,960 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |